The median survival was 16.9 and 16.4 months for patients whose tumor had unexpressed and moderate levels of Tim-3, respectively, whereas the median survival was 7.6 months for those who showed high levels of Tim-3 expression and MGMT promoter nonmethylation. Here, HAVCR2 is linked to neoplasm.